TriSalus Life Sciences Innovates Drug Delivery for Liver and Pancreatic Cancer Treatments

TriSalus Life Sciences Advances Drug Delivery for Challenging Cancers

TriSalus Life Sciences Inc., a prominent player in the oncology-focused medical technology sector, is making significant strides in the treatment of liver and pancreatic tumors. The company’s innovative Pressure-Enabled Drug Delivery™ (PEDD™) technology is designed to enhance drug delivery efficiency while minimizing damage to surrounding healthy tissues. By employing this technology, TriSalus aims to improve therapeutic outcomes for patients afflicted by these challenging cancers, which often resist conventional treatments. The company utilizes two FDA-cleared devices: the TriNav® Infusion System, which facilitates hepatic arterial infusion, and the Pancreatic Retrograde Venous Infusion System, specifically designed for pancreatic tumors.

The PEDD technique modulates pressure and flow to target tumors effectively, thereby increasing the concentration of therapeutic agents where they are needed most. This method not only provides a higher therapeutic index but also reduces the risk of systemic toxicity, a common concern in cancer treatment. In addition to enhancing drug delivery, TriSalus is also focusing on immunotherapy to combat the immunosuppressive environments that often hinder treatment efficacy. Their investigational immunotherapy, nelitolimod, targets TLR9, a receptor that is prevalent in various cancer types, making it a promising candidate for improving immune response in patients with liver and pancreatic cancers.

TriSalus's commitment to advancing oncology care is further exemplified through its collaborations with leading cancer centers across the United States. These partnerships leverage specialized expertise in immuno-oncology, addressing the dual challenges of immune dysfunction and effective drug delivery. The company’s approach is expected to generate valuable clinical insights, particularly as it explores the potential of nelitolimod through the Pressure-Enabled Regional Immuno-Oncology™ (PERIO) method. This multifaceted strategy positions TriSalus at the forefront of innovative cancer treatment, with the potential to significantly enhance patient outcomes.

In related news, TriSalus is set to hold a conference call and webcast on November 14, 2024, to discuss its financial results for the third quarter ending September 30, 2024. This event will provide stakeholders with updates on both financial performance and ongoing developments in the company’s therapeutic pipeline. Interested parties can access the live webcast through TriSalus' investor relations website, with a replay available afterward.

The upcoming conference call is anticipated to offer insights into TriSalus’s operational strategies and future directions in the oncology landscape. As the company continues to refine its innovative technologies and enhance drug delivery mechanisms, it remains dedicated to addressing the unmet needs of patients battling liver and pancreatic tumors.